![](/images/graphics-bg.png)
Infliximab Extends the Duration until the First Surgery in Patients with Crohn’s Disease
المؤلفون المشاركون
Fujiya, Mikihiro
Sakatani, Aki
Ito, Takahiro
Inaba, Yuhei
Ueno, Nobuhiro
Kashima, Shin
Tominaga, Motoya
Moriichi, Kentaro
Okamoto, Kotaro
Tanabe, Hiroki
Ohtake, Takaaki
Furukawa, Hiroyuki
Ashida, Toshifumi
Ikuta, Katsuya
Kohgo, Yutaka
Kono, Toru
المصدر
العدد
المجلد 2013، العدد 2013 (31 ديسمبر/كانون الأول 2013)، ص ص. 1-5، 5ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2013-11-26
دولة النشر
مصر
عدد الصفحات
5
التخصصات الرئيسية
الملخص EN
Background/Aims.
While biological drugs are useful for relieving the disease activity and preventing abdominal surgery in patients with Crohn’s disease (CD), it is unclear whether the use of biological drugs in CD patients with no history of abdominal surgery is appropriate.
We evaluated the effects of infliximab and other factors on extending the duration until the first surgery in CD patients on a long-term basis.
Methods.
The clinical records of 104 CD patients were retrospectively investigated.
The cumulative nonoperation rate until the first surgery was examined with regard to demographic factors and treatments.
Results.
The 50% nonoperative interval in the 104 CD patients was 107 months.
The results of a univariate analysis revealed that a female gender, the colitis type of CD, and the administration of corticosteroids, immunomodulators, or infliximab were factors estimated to improve the cumulative nonoperative rate.
A multivariate analysis showed that the colitis type and administration of infliximab were independent factors associated with a prolonged interval until the first surgery in the CD patients with no history of abdominal surgery.
Conclusions.
This study suggests that infliximab treatment extends the duration until the first surgery in CD patients with no history of abdominal surgery.
The early use of infliximab before a patient undergoes abdominal surgery is therefore appropriate.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Sakatani, Aki& Fujiya, Mikihiro& Ito, Takahiro& Inaba, Yuhei& Ueno, Nobuhiro& Kashima, Shin…[et al.]. 2013. Infliximab Extends the Duration until the First Surgery in Patients with Crohn’s Disease. BioMed Research International،Vol. 2013, no. 2013, pp.1-5.
https://search.emarefa.net/detail/BIM-1031052
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Sakatani, Aki…[et al.]. Infliximab Extends the Duration until the First Surgery in Patients with Crohn’s Disease. BioMed Research International No. 2013 (2013), pp.1-5.
https://search.emarefa.net/detail/BIM-1031052
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Sakatani, Aki& Fujiya, Mikihiro& Ito, Takahiro& Inaba, Yuhei& Ueno, Nobuhiro& Kashima, Shin…[et al.]. Infliximab Extends the Duration until the First Surgery in Patients with Crohn’s Disease. BioMed Research International. 2013. Vol. 2013, no. 2013, pp.1-5.
https://search.emarefa.net/detail/BIM-1031052
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1031052
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)